Optimizing Outcomes for Spondyloarthritis: Focus on Interleukin-23/-17 Inhibitors

What's new in treatments for spondyloarthritis? Learn more about the rationale for novel therapies and the latest data.

Credit available for this activity expires: 03/09/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/988291?ecd=bdc_podcast_libsyn_mscpedu